Greenland Mines Ltd operating divisions include Natural Resources, focused on the exploration and development of the Skaergaard Project in Southeast Greenland. Cell and Gene Therapy, including Klotho's KLTO-202 primary indication for ALS. Greenland Mines Ltd, formerly known as Klotho Neurosciences Inc., is based in CHARLOTTE, N.C.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-10.55M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.17 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -67.98% |
| Return on Assets (Trailing 12 Months) | -60.61% |
| Current Ratio (Most Recent Fiscal Quarter) | 10.09 |
| Quick Ratio (Most Recent Fiscal Quarter) | 10.09 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.43 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 3.18M |
| Free Float | 2.82M |
| Market Capitalization | $10.01M |
| Average Volume (Last 20 Days) | 0.73M |
| Beta (Past 60 Months) | 6.91 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 11.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 20.07% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |